Why Cancer Patients And Doctors Should Rethink The Value Of Phase I Trials
Of all the reports being presented at this year’s big cancer meeting, the one I think most important is not about a particular drug or malignancy. It’s about the design of clinical trials.
For cancer patients trying an experimental drug, participating in a “matched” study–using biomarkers, like genetics, to link their condition to a treatment–offers much greater chances of clinical benefit than does participating in a similar, unmatched study. The abstract*, authored by a geographically wide research group, will be delivered in Chicago by Maria Schwaederlé, PharmD, of the University of California in San Diego.
For cancer patients trying an experimental drug, participating in a “matched” study–using biomarkers, like genetics, to link their condition to a treatment–offers much greater chances of clinical benefit than does participating in a similar, unmatched study. The abstract*, authored by a geographically wide research group, will be delivered in Chicago by Maria Schwaederlé, PharmD, of the University of California in San Diego.